| 翻訳と辞書 |
| Opsona Therapeutics ： ウィキペディア英語版 |
Opsona Therapeutics
Opsona Therapeutics is a drug development company specialising in the human immune system and new drugs and vaccines to prevent and treat autoimmune/inflammatory conditions, cancers and infectious diseases.〔(Article in the Irish Times )〕〔(Sunday Business Post article )〕〔(BusinessWeek company profile )〕
Based in Ireland, Opsona is a spin-out from Trinity College Dublin (TCD).〔(Article in the Irish Times )〕 Ireland is ranked highly in the world in immunology research, and TCD has been at the forefront of the field.〔(Times Higher Educational Supplement - QS World University Rankings 2007 )〕
Opsona's research is primarily focused on the role of Toll-like receptors (TLRs) and TLR signalling in human innate immunity.
The company was founded in 2004 by three immunologists:
*Professor Luke O'Neill〔(Article in the Irish Examiner )〕
*Professor Kingston Mills〔(Article on the Trinity College Dublin website )〕
*Professor Dermot Kelleher〔(Article on the Trinity College Dublin website )〕
Opsona's main investors are international and life-science focused:
*Inventages Venture Capital (Bahamas)〔(Article on Fierce Biotech )〕
*Seroba Bioventures (Ireland)
*GenenFund (USA)
*Enterprise Ireland (Ireland)〔(PR Newswire article )〕
== References ==
抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』
■ウィキペディアで「Opsona Therapeutics」の詳細全文を読む
スポンサード リンク
| 翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|